{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:39:31Z","timestamp":1790293171330,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00415-025-13301-y","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T16:42:29Z","timestamp":1754325749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical efficacy of GLP-1 receptor agonists in the treatment of Parkinson\u2019s disease: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8250-5833","authenticated-orcid":false,"given":"Yujing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"issue":"12","key":"13301_CR1","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE et al (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 30(12):1591\u20131601. https:\/\/doi.org\/10.1002\/mds.26424","journal-title":"Mov Disord"},{"key":"13301_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE (2017) Parkinson disease. Nat Rev Dis Primers 3:17013. https:\/\/doi.org\/10.1038\/nrdp.2017.13","journal-title":"Nat Rev Dis Primers"},{"issue":"10291","key":"13301_CR3","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/s0140-6736(21)00218-x","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C (2021) Parkinson\u2019s disease. Lancet 397(10291):2284\u20132303. https:\/\/doi.org\/10.1016\/s0140-6736(21)00218-x","journal-title":"Lancet"},{"issue":"8","key":"13301_CR4","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","volume":"91","author":"J Jankovic","year":"2020","unstructured":"Jankovic J, Tan EK (2020) Parkinson\u2019s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 91(8):795\u2013808. https:\/\/doi.org\/10.1136\/jnnp-2019-322338","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"13301_CR5","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/mds.27360","volume":"33","author":"AE Lang","year":"2018","unstructured":"Lang AE, Espay AJ (2018) Disease modification in Parkinson\u2019s disease: current approaches, challenges, and future considerations. Mov Disord 33(5):660\u2013677. https:\/\/doi.org\/10.1002\/mds.27360","journal-title":"Mov Disord"},{"key":"13301_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00676-7","author":"MT Henrich","year":"2023","unstructured":"Henrich MT, Oertel WH, Surmeier DJ, Geibl FF (2023) Mitochondrial dysfunction in Parkinson\u2019s disease \u2013 a key disease hallmark with therapeutic potential. Mol Neurodegener. https:\/\/doi.org\/10.1186\/s13024-023-00676-7","journal-title":"Mol Neurodegener"},{"issue":"7656","key":"13301_CR7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature22327","volume":"546","author":"YL Liang","year":"2017","unstructured":"Liang YL, Khoshouei M, Radjainia M, Zhang Y, Glukhova A, Tarrasch J, Thal DM, Furness SGB, Christopoulos G, Coudrat T et al (2017) Phase-plate cryo-EM structure of a class B GPCR-G-protein complex. Nature 546(7656):118\u2013123. https:\/\/doi.org\/10.1038\/nature22327","journal-title":"Nature"},{"issue":"13","key":"13301_CR8","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMe2401743","volume":"390","author":"DG Standaert","year":"2024","unstructured":"Standaert DG (2024) GLP-1, Parkinson\u2019s disease, and neuroprotection. N Engl J Med 390(13):1233\u20131234. https:\/\/doi.org\/10.1056\/NEJMe2401743","journal-title":"N Engl J Med"},{"key":"13301_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cells11132023","author":"G Monti","year":"2022","unstructured":"Monti G, Gomes Moreira D, Richner M, Mutsaers HAM, Ferreira N, Jan A (2022) GLP-1-Receptor agonists in neurodegeneration: neurovascular unit in the spotlight. Cells. https:\/\/doi.org\/10.3390\/cells11132023","journal-title":"Cells"},{"issue":"1","key":"13301_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-024-01025-6","volume":"31","author":"V Wang","year":"2024","unstructured":"Wang V, Tseng KY, Kuo TT, Huang EY, Lan KL, Chen ZR, Ma KH, Greig NH, Jung J, Choi HI et al (2024) Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice. J Biomed Sci 31(1):38. https:\/\/doi.org\/10.1186\/s12929-024-01025-6","journal-title":"J Biomed Sci"},{"key":"13301_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/b978-0-12-381517-0.00013-8","volume":"84","author":"C H\u00f6lscher","year":"2010","unstructured":"H\u00f6lscher C (2010) The role of GLP-1 in neuronal activity and neurodegeneration. Vitam Horm 84:331\u2013354. https:\/\/doi.org\/10.1016\/b978-0-12-381517-0.00013-8","journal-title":"Vitam Horm"},{"key":"13301_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-13-33","volume":"13","author":"K Hunter","year":"2012","unstructured":"Hunter K, H\u00f6lscher C (2012) Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 13:33. https:\/\/doi.org\/10.1186\/1471-2202-13-33","journal-title":"BMC Neurosci"},{"key":"13301_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179583","author":"Y Diz-Chaves","year":"2022","unstructured":"Diz-Chaves Y, Mastoor Z, Spuch C, Gonz\u00e1lez-Mat\u00edas LC, Mallo F (2022) Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23179583","journal-title":"Int J Mol Sci"},{"issue":"7","key":"13301_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"issue":"3","key":"13301_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181\u2013184. https:\/\/doi.org\/10.1136\/jnnp.55.3.181","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"13301_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1586\/17446651.1.3.329","volume":"1","author":"C Triplitt","year":"2006","unstructured":"Triplitt C, DeFronzo RA (2006) Exenatide: first-in-class incretin mimetic for the treatment of type 2 diabetes mellitus. Expert Rev Endocrinol Metab 1(3):329\u2013341. https:\/\/doi.org\/10.1586\/17446651.1.3.329","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"3","key":"13301_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1089\/dia.2005.7.467","volume":"7","author":"T Poon","year":"2005","unstructured":"Poon T, Nelson P, Shen L, Mihm M, Taylor K, Fineman M, Kim D (2005) Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 7(3):467\u2013477. https:\/\/doi.org\/10.1089\/dia.2005.7.467","journal-title":"Diabetes Technol Ther"},{"issue":"5","key":"13301_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/1060028017689878","volume":"51","author":"D McCarty","year":"2017","unstructured":"McCarty D, Coleman M, Boland CL (2017) Lixisenatide: a new daily GLP-1 agonist for type 2 diabetes management. Ann Pharmacother 51(5):401\u2013409. https:\/\/doi.org\/10.1177\/1060028017689878","journal-title":"Ann Pharmacother"},{"issue":"7","key":"13301_CR19","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","volume":"24","author":"SP Yun","year":"2018","unstructured":"Yun SP, Kam TI, Panicker N, Kim S, Oh Y, Park JS, Kwon SH, Park YJ, Karuppagounder SS, Park H et al (2018) Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson\u2019s disease. Nat Med 24(7):931\u2013938. https:\/\/doi.org\/10.1038\/s41591-018-0051-5","journal-title":"Nat Med"},{"key":"13301_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-025-11195-6","author":"A Saran","year":"2025","unstructured":"Saran A, Raisinghani R, Paliwal S, Sharma S (2025) GLP-1R agonists: recent advances, current gaps, and future challenges. Mol Divers. https:\/\/doi.org\/10.1007\/s11030-025-11195-6","journal-title":"Mol Divers"},{"key":"13301_CR21","doi-asserted-by":"publisher","unstructured":"The Unified Parkinson\u2019s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003, 18(7):738\u2013750. https:\/\/doi.org\/10.1002\/mds.10473.","DOI":"10.1002\/mds.10473"},{"issue":"5","key":"13301_CR22","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/mds.27670","volume":"34","author":"RB Postuma","year":"2019","unstructured":"Postuma RB, Berg D (2019) Prodromal Parkinson\u2019s disease: the decade past, the decade to come. Mov Disord 34(5):665\u2013675. https:\/\/doi.org\/10.1002\/mds.27670","journal-title":"Mov Disord"},{"issue":"4","key":"13301_CR23","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1212\/con.0000000000000764","volume":"25","author":"TA Zesiewicz","year":"2019","unstructured":"Zesiewicz TA (2019) Parkinson disease. Continuum (Minneap Minn) 25(4):896\u2013918. https:\/\/doi.org\/10.1212\/con.0000000000000764","journal-title":"Continuum (Minneap Minn)"},{"issue":"10","key":"13301_CR24","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/mds.27802","volume":"34","author":"S Heinzel","year":"2019","unstructured":"Heinzel S, Berg D, Gasser T, Chen H, Yao C, Postuma RB (2019) Update of the MDS research criteria for prodromal Parkinson\u2019s disease. Mov Disord 34(10):1464\u20131470. https:\/\/doi.org\/10.1002\/mds.27802","journal-title":"Mov Disord"},{"issue":"6","key":"13301_CR25","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1365-2990.2007.00874.x","volume":"33","author":"CH Hawkes","year":"2007","unstructured":"Hawkes CH, Del Tredici K, Braak H (2007) Parkinson\u2019s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 33(6):599\u2013614. https:\/\/doi.org\/10.1111\/j.1365-2990.2007.00874.x","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"2","key":"13301_CR26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/s0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Del Tredici K, R\u00fcb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging 24(2):197\u2013211. https:\/\/doi.org\/10.1016\/s0197-4580(02)00065-9","journal-title":"Neurobiol Aging"},{"issue":"6","key":"13301_CR27","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00401-014-1343-6","volume":"128","author":"S Holmqvist","year":"2014","unstructured":"Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Bj\u00f6rklund T, Wang ZY, Roybon L, Melki R, Li JY (2014) Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol 128(6):805\u2013820. https:\/\/doi.org\/10.1007\/s00401-014-1343-6","journal-title":"Acta Neuropathol"},{"issue":"1","key":"13301_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ane.13336","volume":"143","author":"DJ van Wamelen","year":"2021","unstructured":"van Wamelen DJ, Martinez-Martin P, Weintraub D, Schrag A, Antonini A, Falup-Pecurariu C, Odin P, Ray Chaudhuri K (2021) The non-motor symptoms scale in Parkinson\u2019s disease: validation and use. Acta Neurol Scand 143(1):3\u201312. https:\/\/doi.org\/10.1111\/ane.13336","journal-title":"Acta Neurol Scand"},{"issue":"15","key":"13301_CR29","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R et al (2008) Movement disorder society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129\u20132170. https:\/\/doi.org\/10.1002\/mds.22340","journal-title":"Mov Disord"},{"issue":"3","key":"13301_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/bf02260863","volume":"4","author":"V Peto","year":"1995","unstructured":"Peto V, Jenkinson C, Fitzpatrick R, Greenhall R (1995) The development and validation of a short measure of functioning and well being for individuals with Parkinson\u2019s disease. Qual Life Res 4(3):241\u2013248. https:\/\/doi.org\/10.1007\/bf02260863","journal-title":"Qual Life Res"},{"issue":"13","key":"13301_CR31","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/mds.21596","volume":"22","author":"KR Chaudhuri","year":"2007","unstructured":"Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, Ondo W, Abe K, Macphee G, Macmahon D et al (2007) The metric properties of a novel non-motor symptoms scale for Parkinson\u2019s disease: results from an international pilot study. Mov Disord 22(13):1901\u20131911. https:\/\/doi.org\/10.1002\/mds.21596","journal-title":"Mov Disord"},{"key":"13301_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104896","author":"S Bhalla","year":"2022","unstructured":"Bhalla S, Mehan S, Khan A, Rehman MU (2022) Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions. Neurosci Biobehav Rev. https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104896","journal-title":"Neurosci Biobehav Rev"},{"issue":"5","key":"13301_CR33","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","volume":"21","author":"D Athauda","year":"2016","unstructured":"Athauda D, Foltynie T (2016) The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson\u2019s disease: mechanisms of action. Drug Discov Today 21(5):802\u2013818. https:\/\/doi.org\/10.1016\/j.drudis.2016.01.013","journal-title":"Drug Discov Today"},{"issue":"3","key":"13301_CR34","doi-asserted-by":"publisher","first-page":"e10505","DOI":"10.1002\/btm2.10505","volume":"8","author":"Y Wang","year":"2023","unstructured":"Wang Y, Chen WJ, Han YY, Xu X, Yang AX, Wei J, Hong DJ, Fang X, Chen TT (2023) Neuroprotective effect of engineered clostridiumbutyricum-pMTL007-GLP-1 on Parkinson\u2019s disease mice models via promoting mitophagy. Bioeng Transl Med 8(3):e10505. https:\/\/doi.org\/10.1002\/btm2.10505","journal-title":"Bioeng Transl Med"},{"key":"13301_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/nu15163585","author":"VA Ruiz-Pozo","year":"2023","unstructured":"Ruiz-Pozo VA, Tamayo-Trujillo R, Cadena-Ullauri S, Frias-Toral E, Guevara-Ram\u00edrez P, Paz-Cruz E, Chapela S, Montalv\u00e1n M, Morales-L\u00f3pez T, Simancas-Racines D et al (2023) The molecular mechanisms of the relationship between insulin resistance and Parkinson\u2019s disease pathogenesis. Nutrients. https:\/\/doi.org\/10.3390\/nu15163585","journal-title":"Nutrients"},{"issue":"6","key":"13301_CR36","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.14336\/AD.2022.0325","volume":"13","author":"H Yu","year":"2022","unstructured":"Yu H, Sun T, He X, Wang Z, Zhao K, An J, Wen L, Li JY, Li W, Feng J (2022) Association between Parkinson\u2019s disease and diabetes mellitus: from epidemiology, pathophysiology and prevention to treatment. Aging Dis 13(6):1591\u20131605. https:\/\/doi.org\/10.14336\/AD.2022.0325","journal-title":"Aging Dis"},{"issue":"7","key":"13301_CR37","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/nan.12728","volume":"47","author":"E de Pablo-Fern\u00e1ndez","year":"2021","unstructured":"de Pablo-Fern\u00e1ndez E, Courtney R, Rockliffe A, Gentleman S, Holton JL, Warner TT (2021) Faster disease progression in Parkinson\u2019s disease with type 2 diabetes is not associated with increased \u03b1-synuclein, tau, amyloid-\u03b2 or vascular pathology. Neuropathol Appl Neurobiol 47(7):1080\u20131091. https:\/\/doi.org\/10.1111\/nan.12728","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"4","key":"13301_CR38","doi-asserted-by":"publisher","DOI":"10.1080\/21688370.2023.2292461","volume":"12","author":"EM Rhea","year":"2024","unstructured":"Rhea EM, Babin A, Thomas P, Omer M, Weaver R, Hansen K, Banks WA, Talbot K (2024) Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer\u2019s and Parkinson\u2019s diseases. Tissue Barriers 12(4):2292461. https:\/\/doi.org\/10.1080\/21688370.2023.2292461","journal-title":"Tissue Barriers"},{"issue":"3","key":"13301_CR39","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3233\/jpd-191683","volume":"9","author":"S Cerri","year":"2019","unstructured":"Cerri S, Mus L, Blandini F (2019) Parkinson\u2019s disease in women and men: what\u2019s the difference? J Parkinsons Dis 9(3):501\u2013515. https:\/\/doi.org\/10.3233\/jpd-191683","journal-title":"J Parkinsons Dis"},{"issue":"8","key":"13301_CR40","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1001\/jamaneurol.2016.0947","volume":"73","author":"R Savica","year":"2016","unstructured":"Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA (2016) Time trends in the incidence of Parkinson disease. JAMA Neurol 73(8):981\u2013989. https:\/\/doi.org\/10.1001\/jamaneurol.2016.0947","journal-title":"JAMA Neurol"},{"issue":"3","key":"13301_CR41","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.yfrne.2014.02.002","volume":"35","author":"GE Gillies","year":"2014","unstructured":"Gillies GE, Pienaar IS, Vohra S, Qamhawi Z (2014) Sex differences in Parkinson\u2019s disease. Front Neuroendocrinol 35(3):370\u2013384. https:\/\/doi.org\/10.1016\/j.yfrne.2014.02.002","journal-title":"Front Neuroendocrinol"},{"key":"13301_CR42","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab 46:101102. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102","journal-title":"Mol Metab"},{"issue":"3","key":"13301_CR43","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1210\/er.2012-1055","volume":"34","author":"F Mauvais-Jarvis","year":"2013","unstructured":"Mauvais-Jarvis F, Clegg DJ, Hevener AL (2013) The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev 34(3):309\u2013338. https:\/\/doi.org\/10.1210\/er.2012-1055","journal-title":"Endocr Rev"},{"key":"13301_CR44","unstructured":"Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors): Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane 2024. Available from www.cochrane.org\/handbook."},{"issue":"10479","key":"13301_CR45","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","volume":"405","author":"N Vijiaratnam","year":"2025","unstructured":"Vijiaratnam N, Girges C, Auld G, McComish R, King A, Skene SS, Hibbert S, Wong A, Melander S, Gibson R et al (2025) Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet 405(10479):627\u2013636. https:\/\/doi.org\/10.1016\/S0140-6736(24)02808-3","journal-title":"Lancet"},{"issue":"13","key":"13301_CR46","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner WG, Remy P, Giordana C, Malt\u00eate D, Derkinderen P, Hou\u00e9to J-L, Anheim M, Benatru I, Boraud T, Brefel-Courbon C et al (2024) Trial of lixisenatide in early Parkinson\u2019s disease. N Engl J Medicine 390(13):1176\u20131185. https:\/\/doi.org\/10.1056\/NEJMoa2312323","journal-title":"N Engl J Medicine"},{"issue":"1","key":"13301_CR47","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","volume":"23","author":"A McGarry","year":"2024","unstructured":"McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, Lee D, Chang J, Dubow J, Dhall R et al (2024) Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 23(1):37\u201345. https:\/\/doi.org\/10.1016\/S1474-4422(23)00378-2","journal-title":"Lancet Neurol"},{"issue":"10103","key":"13301_CR48","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J et al (2017) Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390(10103):1664\u20131675. https:\/\/doi.org\/10.1016\/S0140-6736(17)31585-4","journal-title":"Lancet"},{"key":"13301_CR49","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3233\/JPD-169900","volume":"6","author":"M Tagliati","year":"2016","unstructured":"Tagliati M, Hogg E, Tan E, Talbot K (2016) A phase II, randomized, double-blinded, placebo-controlled trial of liraglutide in Parkinson\u2019s disease. J Parkinson\u2019s Dis 6:218. https:\/\/doi.org\/10.3233\/JPD-169900","journal-title":"J Parkinson\u2019s Dis"},{"issue":"6","key":"13301_CR50","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1172\/JCI68295","volume":"123","author":"I Aviles-Olmos","year":"2013","unstructured":"Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, Whitton P, Wyse R, Isaacs T, Lees A et al (2013) Exenatide and the treatment of patients with Parkinson\u2019s disease. J Clin Investig 123(6):2730\u20132736. https:\/\/doi.org\/10.1172\/JCI68295","journal-title":"J Clin Investig"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13301-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13301-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13301-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:34:28Z","timestamp":1760524468000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13301-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["13301"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13301-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"555"}}